JAK Inhibitors Target Arthritis | Chemical & Engineering News
Volume 90 Issue 48 | p. 19 | Concentrates
Issue Date: November 26, 2012

JAK Inhibitors Target Arthritis

Department: Business
Keywords: JAK inhibitor, rheumatoid arthritis

Incyte has earned a $50 million milestone payment from Eli Lilly & Co. for the initiation of Phase III trials on baricitinib, Incyte’s oral treatment for rheumatoid arthritis. Incyte disclosed the payment a week after FDA approved Pfi­zer’s oral rheumatoid arthritis drug Xeljanz. Both drugs are JAK inhibitors, which target signaling pathways inside cells that play a role in the inflammation involved in arthritis. Pfizer says Xeljanz is the first JAK inhibitor for rheumatoid arthritis and the first new oral rheumatoid drug in more than 10 years.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment